Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen
US-2017267750-A1 · Sep 21, 2017 · US
Monoclonal antibody, and use thereof
US9155805B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9155805-B2 |
| Application number | US-201013202330-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 20, 2010 |
| Priority date | Feb 20, 2009 |
| Publication date | Oct 13, 2015 |
| Grant date | Oct 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
[Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.
First claim
Opening claim text (preview).
What is claimed is: 1. A monoclonal antibody that binds specifically to a protein having the same amino acid sequence as sequence No. 1 or a partial peptide of the protein, recognizing an epitope presented in an amino acid sequence of sequence No. 6, comprising a CDR1, CDR2 and CDR3 of an antibody H chain V region having the amino acid sequences set forth in SEQ ID NOS:20, 21, and 22, respectively; and a CDR1, CDR2 and CDR3 of an antibody L chain V region having the amino acid sequ…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Physics · mapped topic
Physics · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9155805B2 cover?
- [Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cel…
- Who is the assignee on this patent?
- Hamakubo Takao, Mochizuki Yasuhiro, Aburatani Hiroyuki, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification A61K51/1072. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).